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Purpose: Recently, two alternatively spliced survivin variants, survivin-ΔEx3 and survivin-2B, were identified in a single 
copy of the survivin gene. It has been reported that the expressions of survivin splice variants significantly correlates with the 
clinical results in many types of human carcinoma. We investigated the transcription levels of survivin and its splice variants 
in human colorectal carcinomas, and analyzed correlations between survivin expression levels and clinicopathologic 
features.  Methods: We used Western blot and real-time quantitative reverse transcription polymerase chain reaction 
(RT-PCR) to analyze the protein and mRNA expression levels of survivin variants in 51 colorectal carcinomas. The quantita-
tive RT-PCR was performed using primer pairs specific for survivin and each of its splice variants, then normalized for the 
gene that encodes glyceraldehydes-3-phosphate dehydrogenase. Results: In Western blotting, the protein levels of survivin 
were higher in the tumor tissue than in normal tissue. The expression of survivin, survivin-2B and survivin-ΔEx3 mRNA 
was present in 96%, 64.7%, and 82.4% of the samples, respectively. When the pathologic parameters were compared, color-
ectal cancers of advanced pT stages showed significant decrease in survivin-2B mRNA expression by the quantitative 
RT-PCR (P ＜  0.001). Conclusion: The decreased expression of survivin-2B might be related to tumor progression in color-
ectal cancers. This finding indicates that alternatively spliced variants of survivin may be involved in refining the functions of 
survivin during tumor progression.
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INTRODUCTION
Genome-wide analysis of alternative splicing has in-
dicated that 35 to 59% of human genes have alternatively 
spliced forms, and that 70 to 88% of alternative splices gen-
erates a multitude of variants that have overlapping but 
distinct functions [1]. Alternatively spliced forms of key 
proteins in cancer, such as TP53, MDM2, and c-MYC, have 
been shown to play roles in oncogenesis [2-4]. 
Survivin, which is a novel member of the inhibitor of 
apoptotic protein (IAP) family, is markedly over-ex-
pressed in most types of human carcinomas. It has been in-
vestigated with regard to its correlation with clinical re-
sults and its potential as a target for anticancer therapy [5]. Expression of the survivin-2B in colorectal carcinoma
thesurgery.or.kr 405
Two alternatively spliced survivin variants, survivin-Δ
Ex3 and survivin-2B, were recently identified in a single 
copy of the survivin gene [6]. Currently, there is no strong 
evidence to suggest that survivin splice variants are in-
volved in tumorigenesis. However, there have been re-
ports that the expression of survivin splice variants sig-
nificantly correlates with the clinical results in many types 
of human carcinoma, including neuroblastoma, renal cell 
carcinoma, gastric cancer, brain tumor, leukemia, and 
breast cancer. Many investigators have suggested that sur-
vivin-ΔEx3 and survivin-2B play opposing roles in tumor 
progression and/or tumorigenesis [7-12]. 
The over-expression of survivin in colorectal carcinoma 
has been identified as an independent prognostic factor 
[13,14]. However, few reports had addressed on the corre-
lation between survivin splice variants and the clinical re-
sults of colorectal cancer [15]. 
Therefore we investigated the expression levels of sur-
vivin and its splice variants in human colorectal carcino-
mas and assessed the relationship between the expression 
of survivin splice variants and the clinicopathologic 
parameters.
METHODS
Patients
The present study included 51 primary colorectal carci-
noma patients who were admitted between January 2003 
and December 2004. These patients had not received che-
motherapy or radiation therapy before undergoing tumor 
resection. There were 35 males and 16 females, and the me-
dian age of the patients was 65 years (range, 32 to 92 years). 
According to the American Joint Committee on Cancer 
classification, the numbers of patients with stage I, II, and 
III cancer were 19, 9, and 23, respectively. 
We obtained paired colorectal cancerous and adjacent 
normal mucosa from each patient at the time of surgery. 
The samples were immediately frozen in liquid nitrogen 
and stored at －80
oC until use. 
Western blotting 
 Fresh frozen tissues were evenly ground with a homog-
enizer, and cell lysis was performed with the Pro-PREP 
Protein Extraction solution (Intron Biotechnology, Seong-
nam, Korea) in a cold room at 4
oC. Protein extracts were 
obtained by centrifugation at 14,000 rpm for 5 minutes at 
4
oC. The protein content was measured by the Bradford 
assay method, and the samples were heated for 8 minutes 
for denaturation. Next, 40 mg of protein was electro-
phoresed in a 14% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis gel and transferred to a nitrocellulose 
membrane. The blot was incubated in blocking buffer (4% 
nonfat milk, 20 mM Tris [pH 7.5], 500 mM NaCl, 0.1% 
Tween-20) for 1 hour, and was incubated with affinity-pu-
rified rabbit anti-human survivin antibody (1:1,000 dilu-
tion; R&D Systems Inc., Minneapolis, MN, USA) over-
night at 4
oC. After three washes for 10 minutes each, an-
ti-rabbit Ig horseradish peroxidase-conjugated whole an-
tibody from donkey (1:2,000; Amersham Biosciences, 
Uppsala, Sweden) was added, and was incubated for 1 
hour. The blot was then washed three times and the bands 
were detected with the ECL Plus kit (Amersham 
Biosciences).
Reverse transcription
The RNAs from the colorectal cancer tissues, which 
were stored at －80
oC, were extracted using totally RNA 
(Ambion, Austin, TX, USA) and purified with the RNeasy 
kit (Qiagen, Hilden, Germany), to eliminated DNA con-
tamination. The integrity of the extracted RNA was ana-
lyzed by agarose electrophoresis and confirmed by intact 
18S/28S rRNA bands. The RNA was reverse-transcribed 
together with oligo (dT) primer using the Power cDNA 
Synthesis kit (Intron Biotechnology). First, 1 μg of RNA 
was incubated in 20 μL of a solution that contained 1 μL 
RNase inhibitor, 4 μL of 5 × reverse transcriptase (RT) buf-
fer, 2 μL dNTP, 2 μL dithiothreitol, 0.5 μL avian myelo-
blastosis virus RT enzyme at 42
oC for 60 minutes. The re-
action was ended after incubation at 70
oC for 5 minutes. 
Quantitative real-time PCR 
Quantitative real-time reverse transcription polymer-
ase chain reaction (RT-PCR) was performed in triplicate in 
384-well plates; each 20-μL reaction consisted of 10 μL of 
SYBR Green Master Mix (Applied Biosystems, Foster City, Gyu-Seok Cho, et al.
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Fig. 1. Western blotting for survivin in colon cancer tissues. Normal
colon (N) and colon cancer (T) tissues were analyzed in a 15% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis gel. 
Single and distinct bands of approximately 18.1 kDa are evident, 
indicating the presence of the survivin protein.
Fig. 2.  Specificities of the amplification products detected by 
agarose gel electrophoresis, with distinct bands of the calculated 
sizes for all polymerase chain reaction (PCR) products at the 
end-point of 50 PCR cycles. GAPDH, glyceraldehydes-3- 
phosphate dehydrogenase.
CA, USA), 0.8 μL of 10 pM forward and reverse primers for 
the  survivin gene, its splice variants or the glycer-
aldehydes-3-phosphate dehydrogenase (GAPDH) gene. 
The PCR conditions were 50
oC for 2 minutes and 95
oC for 
10 minutes, followed by 40 cycles of 95
oC for 30 seconds, 
60
oC for 30 seconds, and 72
oC for 30 seconds. The sequence 
of the common forward primer for the survivin variants 
was 5'-GACCACCGCATCTCTACATTC-3'. To distinguish 
the three splice variants of survivin, the following reverse 
primers were used: for survivin, 5'-TGCTTTTTATGTT-
CCTCTATGGG-3'; for survivin-2B, 5'-AAGTGCTGGTAT-
TACAGGCGT-3'; and for survivin-ΔEx3, 5'-ATTGTTGG-
TTTCCTTTGCATG-3'. The primers for GAPDH were: for-
ward, 5'-TTGGTATCGTGGAAGGACTCA-3'; and rever-
se, 5'-TGTCATCATATTTGGCAGGTTT-3'. Each of the 
384-well quantitative RT-PCR plates included serial dilu-
tions (1, 0.5, and 0.25) of cDNA, which were used to gen-
erate relative standard curves for the survivin variant 
genes and GAPDH. The GAPDH copy numbers (external 
standard) were used to normalize the copy numbers of the 
different survivin variants, by calculating the ratios of the 
relative mRNA levels.
 The data of relative gene expression was analysed using 
the 2
-ΔΔCt method, where ΔΔCt = (Ct,Target － Ct,GAPDH)Time×  
－  (Ct,Target －  Ct,GAPDH)Time 0. The Time x is any time point 
and Time 0 represents the 1X expression of the target gene 
normalized to GAPDH. The real-time RT-PCR analysis 
was performed on the Prism 7900 Sequence Detection 
System (Applied Biosystems). 
The relative amounts of survivin variant mRNAs were 
determined by dividing the amount of the survivin var-
iant mRNAs by the amount of GAPDH mRNA for each 
sample. We examined the potential correlation between 
the transcription expression levels of the survivin variants 
and clinicopathologic factors.
Statistical analysis
Statistical analysis was performed using the Mann- 
Whitney test with the SPSS (SPSS Inc., Chicago, IL, USA). 
A P-value of less than 0.05 was considered to indicate stat-
istical significance.
RESULTS
Expression of survivin variant genes 
In the Western blots of the colorectal cancer tissues, sin-
gle discrete band of approximately 18.1 kDa was observed, 
indicating the presence of the survivin protein. The tumor 
tissues express survivin 10 to 15 times more than normal 
ones (Fig. 1). The specificities of the amplification prod-
ucts were confirmed by agarose gel electrophoresis, in 
which distinct bands of the calculated sizes were detected 
for all PCR products at the end-point (Fig. 2). Among the 
51 tumor samples, survivin mRNA was the most domi-
nant transcript and was present in 96% (49/51) of the sam-
ples; 64.7% (33/51) of the samples demonstrated survi-
vin-2B expression, and 82.4% (41/51) of the samples Expression of the survivin-2B in colorectal carcinoma
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Table 1. Correlation between the expression levels of survivin and its variants and the clinicopathologic parameters
Parameters No. of patients
P-value
Sur/GAPDH Sur-2B/GAPDH Sur-ΔEx3/GAPDH Sur-2B/Sur Sur-ΔEx3/Sur
Stage (UICC)
　I ＋  II 28 0.400 0.676 0.497 0.870 0.350
　III 23
T stage
　T1 ＋  T2 24 0.260 0.001 0.195 0.065 0.715
　T3 ＋  T4 27
N stage
　N (－) 28 0.400 0.676 0.497 0.870 0.350
　N (＋)2 3
Age (yr)
　≤65 25 0.764 0.699 0.420 0.187 0.257
　＞65 26
Sex
　Male 35 0.845 0.349 0.830 0.984 0.419
　Female 16
GAPDH, glyceraldehydes-3-phosphate dehydrogenase; UICC, International Union Against Cancer.
showed survivin-ΔEx3 expression.
Correlation between the expression levels of the 
survivin variants and clinicopathologic parameters
The expression of survivin-2B decreased along with the 
invasive depth of the tumor with statistical significance (P 
＜  0.001), while the expression levels of survivin and sur-
vivin-ΔEx3 did not show any relationship with any of the 
investigated clinicopathologic factors (Table 1, Fig. 3).
To ensure that the depth-dependent decrease of survi-
vin-2B expression was not the result of a depth-dependent 
increase of the GAPDH transcript used as the external 
standard, we also calculated the ratios of the mRNA levels 
between survivin- ΔEx3 and survivin-2B on the one hand, 
and survivin as an internal standard on the other hand. 
Since all of the survivin variants are derived from a com-
mon hnRNA precursor pool, these ratios are independent 
of any potential bias imposed by possible variations of the 
GAPDH expression levels. We did not find any significant 
change in the relative mRNA levels between survivin and 
its variants, which supports the observed depth-depend-
ent decrease in survivin-2B expression (Table 1, Fig. 4).
DISCUSSION
Colorectal cancer is one of the leading causes of death 
worldwide, and many researches have been performed on 
the development and progression of this tumor. The de-
velopment of colorectal cancer proceeds through a series 
of genetic changes that involve the activation of oncogenes 
and the loss of tumor suppressor genes. During this proc-
ess, a disturbance of the balances between cell pro-
liferation and apoptosis may underlie neoplastic develop-
ment [16]. Cell death is caused by necrosis and apoptosis, 
with apoptosis playing an important role in homeostatic 
maintenance in mature human organs by removing sen-
escent and unneeded cells [17]. Unfortunately, cancerous 
cells may continue to grow by inhibiting the apoptosis in-
duced by natural defense products, such as bcl-2 [18], 
heat-shock protein [19], and members of the IAP family 
[20]. In addition, these antiapoptotic products may facili-
tate the accumulation of transforming mutations and pro-
mote resistance to anticancer chemotherapy [21,22].
Among the antiapoptotic products, the IAP family has 
been recently discovered. IAP family members directly in-
hibit activated caspase 3 and caspase 7, and inhibit the acti-
vation of pro-caspase 9. There are several lines of evidence 
that they also indirectly inhibit caspase 1 and caspase 2 as Gyu-Seok Cho, et al.
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Fig. 4. Ratios of the relative mRNA levels between survivin and its variants in colorectal cancer. No significant change is evident in relation 
to T stage. Top line represents largest value, bottom line represents smallest value, the upper line of the box represents upper quartile, the 
lower line of the box represents lower quartile, and inner line of the box represents median value.
well [21,22]. The IAP family has been shown to protect 
cells from various types of apoptosis inducing agents and 
to block apoptosis generated by various stimuli, such as 
various anticancer drugs, irradiation, and ultraviolet irra-
diation; thus, the IAP family plays a key role in the for-
mation of cancer [19]. 
The locus of survivin, which is a recently discovered 
member of the IAP family, is at 17q25. Survivin consists of 
Fig. 3. GAPDH-normalized mRNA levels of survivin and its 
variants in colorectal cancers in relation to the different 
variables. A significant decrease in the expression of 
survivin-2B is noted in advanced T stage (pT3) patients. Top 
line representslargest value, bottom line represents smallest 
value, the upper line of the box represents upper quartile, the 
lower line of the box represents lower quartile, and inner line of 
the box represents median value.Expression of the survivin-2B in colorectal carcinoma
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142 amino acids and has a molecular mass of 16.5 kDa [23]. 
Unlike other members of the IAP family, survivin shows 
high-level expression during the fetal period and negli-
gible expression in normally differentiated tissues after 
birth. However, studies have shown that the expression of 
survivin increases in cancer cells [20]. Discoveries of the 
expression of survivin in tissues of various cancers, such 
as lung, colon, stomach, breast, prostate, and pancreatic 
cancers, as well as neuroblastomas and highly differ-
entiated lymphomas have brought survivin to the fore-
front of research efforts [5]. 
Survivin mRNA has been detected in 67.3% of colon 
cancer tissues, and the expression of survivin has been 
found to be significantly higher in colon cancer tissues [14] 
compared to the normal tissue. The human survivin genes 
have four dominant (1, 2, 3, and 4) and two hidden (2B and 
3B) exons. Their own pre-mRNA creates four mRNAs 
with different conjugations of splices, which are des-
ignated as the survivin, survivin-2B, survivin-ΔEx3, and 
survivin-3B proteins [6]. Survivin-ΔEx3, which lacks 
exon 3, and survivin-2B, which has intron 2 as an addi-
tional cryptic exon, has been studied in detail [6,24]. In the 
colon mucosa, survivin is preferentially expressed in the 
lower portion of normal colon crypts where adult stem 
cells and other proliferative cells reside and its expression 
decreases from crypt bottom to top as the cells progress to 
differentiate [25]. The survivin intensively expressed in 
many fetal tissues in contrast with downregulation in 
most nonproliferating adult tissues. However, re-
expression of survivin was found in the most common hu-
man cancer types, which might promote both tumor pro-
gression and resistance to treatment with anticancer drugs 
and irradiation. The biochemical a mechanism by which 
survivin suppresses apoptosis remains under investi-
gation. 
In this study, the survivin-2B was decreased in ad-
vanced pT3 stages in contrast with the relative increase in 
early stages (pT1 ＋  2). The downregulation of survivin-2B 
might weaken its functional antagonism, and moreover, 
could permit the generation of more survivin or survivin- 
ΔEx3 because three survivin variants come from the same 
pool of an hnRNA precursor. Thus, the decrease in survi-
vin-2B may result in development and invasion of the col-
orectal carcinoma. Mahotka et al. [8] and Meng et al. [9] al-
so reported that survivin-2B decreased according to the 
higher clinical stages and invasive depth in renal cell carci-
noma and gastric carcinoma, respectively. 
Islam et al. [7] have reported that high level of survivin 
mRNA expression were significantly associated with ad-
vanced stages of neuroblastomas; survivin-2B expression 
was predominant in some favorable neuroblastoma, while 
it was low and ubiquitous in most normal and malignant 
tissues. Krieg et al. [26] have reported that survivin-2B is 
significantly decreased in the later stages of stomach 
cancer. Meng et al. [9] have reported that survivin-2B is 
significantly related to the initial stage, differentiation, 
and infiltration of the lesion among stomach cancer pa-
tients, while survivin-ΔEx3 is significantly correlated 
with apoptosis. Nakagawa et al. [11] have reported that 
survivin-ΔEx3 is more conspicuous than survivin-2B in 
the bone marrow tissues of acute and chronic lymphatic 
leukemia patients. In summary, researchers have pointed 
out that survivin-ΔEx3 show a clear antiapoptotic func-
tion, while survivin-2B greatly decreases the antiapoptotic 
function of survivin. Therefore, survivin-ΔEx3 and survi-
vin-2B play important opposite roles in the generation and 
progression of tumors.
Recently, Suga et al. [15] have reported the correlation of 
the stages in patients of colorectal cancer with clin-
icopathologic factors. According to this study, GAPDH- 
normalized mRNA of survivin and its splicing variants 
have no correlated with the stage, survivin-2B/survivin 
has the only correlation. In this study, we also could not 
find the correlation with stages. However we subdivided 
to T and N stage and analyzed the correlation respectively. 
Consequently, we found that the level of GAPDH-normal-
ized survivin-2B mRNA decreases significantly as the 
depth of the lesion increases.
In conclusion, survivin was expressed to a greater ex-
tent in colon cancer tissues than in normal tissues. 
However, when survivin and its variants were separated 
and the quantities of mRNA were measured, only survi-
vin-2B showed a significant difference in expression, 
which was dependent upon the depth of the lesion and ap-
peared to correlate with the progression of colon cancer. 
This study presents that the expression of survivin-2B Gyu-Seok Cho, et al.
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decreases according to the depth of invasion in the color-
ectal carcinoma, although those of survivin and survivin-
ΔEx3 have not related with the tumor progression and 
stage. Determining the expression pattern of survivin var-
iants in each sample might have a practical usefulness in 
better classifying patients whom would be subjected to 
therapies based on targeting survivin mRNA or protein. 
Further studies for elucidating the exact role of survivin 
variants in tumorigenesis of colorectal tissues along with 
their roles related to recurrence, progression, and patient 
survival are needed.
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